Dong suggested that mutated lung adenocarcinomas with increased mutation burden showed remarkable medical benefit to PD-1 inhibitors [21]

Dong suggested that mutated lung adenocarcinomas with increased mutation burden showed remarkable medical benefit to PD-1 inhibitors [21]. with reduced progression-free (= 0.024) and overall… Read More »Dong suggested that mutated lung adenocarcinomas with increased mutation burden showed remarkable medical benefit to PD-1 inhibitors [21]

3)

3). (41%), leiomyosarcoma (20%), and undifferentiated pleomorphic sarcoma (16%) were the three major types identified. Dedifferentiated liposarcoma and leiomyosarcoma showed higher levels of PD-L1 expression… Read More »3)